Arena International Events Group

Disclaimer: All opinions, ideas, and thoughts expressed and posted by Contributors at BiopharmaTrend.com platform are their own personal points of view, and do not represent neither Contributor's employers, nor BiopharmaTrend.com.

As modern medicine advances, the global clinical supply chain needs to keep up, and the expanding market for stem-cell and gene therapy is making this increasingly complex for companies doing research and development in these areas. The therapeutic potential for stem-cell and gene products is vast, with targeted personalized medicine to suit the individual needs of sick patients, but running clinical supply operations in these fields can come at a high cost and requires detailed planning.

This website uses cookiesWe use cookies to personalise content and to analyse our traffic. We also share information about your use of our site
with our analytics partners who may combine it with other information that you’ve provided to them or that they’ve collected
from your use of their services. You consent to our cookies if you continue to use our website. Read more details in our
cookies policy.